NAD+ Injection Side Effects: Safety Questions Before Treatment

NAD+ injections have incompletely characterized safety, and FDA has reported serious reactions associated with injectable NAD+ products. A prescription or a clinic setting does not establish that a compounded product is FDA-approved. Before treatment, ask both what benefit is supported for your goal and how the specific preparation is made and monitored.¹²

This guide separates reports of harm, general injectable-drug concerns, and what a small human study actually measured. It does not give injection instructions, doses, or a way to manage a reaction at home.

If a reaction is happening now

Difficulty breathing, swelling of the throat or tongue, or fainting can indicate a serious allergic reaction. Seek emergency care immediately and call 911; MedlinePlus describes anaphylaxis as a medical emergency.³ Do not wait for an online consultation to reply.

For severe chills, shaking, vomiting, marked fatigue, or another concerning change after NAD+ treatment, obtain prompt medical assessment and tell the treating team exactly what was administered. FDA has received reports of those symptoms after injectable NAD+, with some people requiring treatment.¹ A symptom should not be dismissed as “detox” or proof that the product is working. Its cause needs assessment.

The FDA warning is about product quality as well as symptoms

FDA warns that some compounders have used food-grade NAD+ to prepare intravenous products. Such ingredients may be unsuitable for sterile drugs without appropriate processing because of microbial and endotoxin contamination risks. The reported reactions were consistent with excessive endotoxin exposure.¹

That statement does not establish that every reaction has the same cause, that every NAD+ product is contaminated, or how often reactions occur. It does establish a concrete safety issue to discuss. A substance being present naturally in the body says little about the sterility and quality of a vial intended for injection.

Compounded is not the same as approved

FDA does not approve compounded drugs or verify their safety, effectiveness, and quality before marketing. Compounding can serve a legitimate clinical need, but poor-quality preparations can harm patients. The agency highlights contamination and inappropriate strength among potential problems.²

Keep the questions separate: is the prescriber licensed, is the pharmacy appropriately licensed, and is this particular drug FDA-approved? A reassuring answer to the first two does not answer the third. Similarly, “pharmaceutical grade,” “tested,” or a certificate image should prompt a specific discussion of what was tested, when, and for which lot—not an assumption that every aspect of safety has been established.

Ask the prescriber who is responsible for questions after dispensing and what information accompanies the medication. A legitimate clinical decision should include the uncertainty, not only the proposed benefit.

What the often-cited infusion pilot tells us

A 2019 pilot followed eight people receiving an intravenous NAD+ infusion and three controls. It measured NAD+ and related metabolites in plasma and urine during and after a six-hour infusion.⁴

This was a small pharmacokinetic experiment, not a trial showing better concentration, improved memory, or durable relief of brain fog. It cannot estimate uncommon harms or establish the safety of repeated treatment over months. Its infusion findings also do not automatically apply to a subcutaneous product, a different concentration, or a preparation from another pharmacy.

Those limitations do not mean that no human NAD-related research exists. They mean the study design must match the claim being made. Our NAD+ research hub separates routes and outcomes, and NAD+ IV and mental clarity examines the cognitive claim more closely. Biomarker movement is not evidence of a benefit to daily thinking.

Questions worth asking before a prescription

Use these as discussion prompts, not a product-certification checklist:

• •What specific problem are we trying to treat, and what human evidence supports this route for that problem?
• •Why is a compounded injection being considered instead of other approaches to the symptom?
• •Which pharmacy prepares it, and can I receive the label, lot information, and written handling instructions?
• •What should I do if a symptom occurs, and whom can I contact promptly?
• •How will we decide whether treatment helped, and when will the plan be reviewed?

There should be room to decide against treatment if the expected benefit is too uncertain. A sales page is not the place to resolve your personal medical history or medication risks. If your goal is clearer thinking, what causes brain fog can help prepare a broader assessment instead of treating fog as evidence of an NAD+ deficiency.

Reporting a problem helps identify patterns

After obtaining care, patients and healthcare professionals can report serious problems through FDA MedWatch. Include the product and manufacturer or pharmacy information when available, the lot number, the timing, and what occurred. Reporting does not replace treatment or prove causation; it helps regulators investigate signals.⁵

Save the dispensing label and relevant records for the clinical team. Ask them how to handle any remaining product; do not reuse it to see whether the reaction happens again. The useful safety discussion covers the proposed benefit, the product’s quality, and a clear response plan—not a promise that injections are safe because NAD+ is natural.